Danske Bank A S Raises Position in Humana Inc. $HUM

Key Points

• Danske Bank A/S increased its Humana stake by 87.4% in Q4 to 108,319 shares (about 0.09% of the company), against a backdrop of roughly 92% institutional ownership.
• Several brokers have raised price targets (many in the ~$264–$290 range), but consensus remains "Hold" with an average target near $247.61 and a split of buy/hold/sell ratings.
• Humana beat Q1 estimates (EPS $10.31 vs. $9.97) and set FY2026 guidance around 9.00 EPS, yet flagged Medicare payment pressure and declining Star ratings as risks that could limit margin recovery.

Danske Bank A S raised its holdings in Humana Inc. (NYSE:HUM - Free Report) by 87.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 108,319 shares of the insurance provider's stock after buying an additional 50,509 shares during the period. Danske Bank A S owned approximately 0.09% of Humana worth $27,744,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of HUM. Vanguard Group Inc. increased its stake in Humana by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 14,261,860 shares of the insurance provider's stock valued at $3,652,890,000 after purchasing an additional 106,030 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its position in Humana by 28.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,496,775 shares of the insurance provider's stock valued at $1,151,759,000 after acquiring an additional 1,008,514 shares during the last quarter. Capital International Investors purchased a new stake in Humana in the third quarter valued at $707,670,000. Invesco Ltd. lifted its position in Humana by 1.3% in the third quarter. Invesco Ltd. now owns 2,043,460 shares of the insurance provider's stock valued at $531,647,000 after acquiring an additional 25,938 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in Humana by 161.5% in the third quarter. Bank of New York Mellon Corp now owns 1,717,767 shares of the insurance provider's stock valued at $446,911,000 after acquiring an additional 1,060,767 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Humana news, insider Sanjay K. Shetty acquired 810 shares of the company's stock in a transaction dated Monday, February 23rd. The stock was bought at an average price of $185.21 per share, with a total value of $150,020.10. Following the completion of the transaction, the insider directly owned 11,657 shares of the company's stock, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.20% of the stock is owned by insiders.

Humana News Roundup

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Multiple brokers lifted price targets sharply (Jefferies, Mizuho, Cantor, Evercore, Truist, Leerink, Deutsche Bank), signaling renewed upside expectations and analyst confidence after the quarter. Jefferies PT to $290 Mizuho PT to $290 Cantor PT to $264
• Positive Sentiment: Company aims for at least a 3% Medicare Advantage margin by 2028 while preparing 2027 bids and integrating MaxHealth — a clear operational target that can support future margin recovery. MA margin target article
• Positive Sentiment: Deutsche Bank and other shops issued constructive commentary/forecasts supporting the stock after Q1, reinforcing buy-side interest. Deutsche Bank positive forecast
• Neutral Sentiment: Sector context: Humana was one of the top performers in April (≈+36%), nearly neck-and-neck with UnitedHealth; market rotation and sector momentum are lifting valuation comparisons. April returns piece
• Neutral Sentiment: Analyst consensus remains around "Hold"/"Market Perform" despite PT changes, so expectations are mixed rather than uniformly bullish. Consensus Hold report
• Negative Sentiment: Goldman raised its target to $195 but kept a sell rating — signaling conviction that the current price is rich versus fundamentals and creating downside pressure. Goldman sell rating
• Negative Sentiment: JPMorgan raised its target to $214 but kept a neutral rating — the PT implies downside from current levels and highlights lingering skepticism about sustainability of margins. JPMorgan PT to $214
• Negative Sentiment: Despite beating Q1 estimates, Humana warned Medicare payments may not keep pace with costs and reported a decline in Medicare Advantage Star ratings; those operational/framing issues are cited by multiple outlets as reasons the stock is under pressure. Q1 beat but Star ratings concern Bloomberg Law

Analysts Set New Price Targets

A number of equities research analysts have recently commented on HUM shares. Cantor Fitzgerald upped their target price on shares of Humana from $201.00 to $264.00 in a report on Thursday. Wolfe Research dropped their price target on shares of Humana from $325.00 to $250.00 and set an "outperform" rating on the stock in a research note on Monday, April 6th. Raymond James Financial restated an "outperform" rating and set a $260.00 target price on shares of Humana in a research report on Friday. Guggenheim upped their target price on shares of Humana from $252.00 to $269.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, UBS Group increased their price target on shares of Humana from $195.00 to $262.00 and gave the company a "neutral" rating in a research report on Thursday. Seven analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Humana currently has an average rating of "Hold" and an average price target of $247.61.

Humana Stock Performance

Shares of HUM opened at $233.87 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.00 and a current ratio of 1.77. The company has a market capitalization of $28.08 billion, a price-to-earnings ratio of 25.01, a PEG ratio of 2.50 and a beta of 0.67. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $315.35. The company's 50 day simple moving average is $188.41 and its 200 day simple moving average is $227.22.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping analysts' consensus estimates of $9.97 by $0.34. The company had revenue of $39.65 billion for the quarter, compared to the consensus estimate of $39.37 billion. Humana had a net margin of 0.82% and a return on equity of 10.45%. Humana's revenue was up 23.5% on a year-over-year basis. During the same quarter last year, the firm posted $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. On average, sell-side analysts predict that Humana Inc. will post 9.06 EPS for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, June 26th. This represents a $3.54 annualized dividend and a dividend yield of 1.5%. Humana's dividend payout ratio is presently 37.86%.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.